Allgemeines
Lupin Neurosciences setzt auf die
Zusammenarbeit mit Angehörigen von
Gesundheitsberufen, um wissenschaftlich
basierte Lösungen zu entwickeln, die über den
Zugang zu lebensverändernden
Behandlungsmöglichkeiten hinausreichen, um
die Patientenversorgung bei unterversorgten
neurologischen Erkrankungen zu optimieren.
2024 Congresses
IDMC -14: The 14th International Myotonic Dystrophy Consortium Meeting, 09-13 April 2024, Nijmegen, The Netherlands
-
- Age, family history and genetic testing data from myotonic dystrophy patients and carers participating in ENSA survey
- ENSA:RevEal the burdeN on daily life for myotonic dyStrophy patients due to myotoniA: key findings of the ENSA surve
- Patient reported satisfaction in myotonic dystrophy management: ENSA international survey suggests benefits of Italian routine practice
8th International Myology Congress, 22-25 April, 2024, Paris, France
- Expert insights: A Delphi-driven neurologists’ panel: real-world mexiletine use in patients with myotonic disorders in Italy
- Development of an auto-questionnaire to measure the impact of non-dystrophic myotonia on patients’ daily lives
- Design and objective of HERCULES and ATLAS: randomised, double-blind, placebo-controlled, multi-centre Phase 3 study investigating once-daily mexiletine prolonged release in myotonic dystrophy types 1 and 2